Loading…
Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds
This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil. Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain...
Saved in:
Published in: | Pharmaceutical research 2001-07, Vol.18 (7), p.957-963 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883 |
---|---|
cites | |
container_end_page | 963 |
container_issue | 7 |
container_start_page | 957 |
container_title | Pharmaceutical research |
container_volume | 18 |
creator | DAGENAIS, Claude JIAN ZONG DUCHARME, Julie POLLACK, Gary M |
description | This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil.
Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains.
Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo.
P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux. |
doi_str_mv | 10.1023/A:1010984110732 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71080124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71080124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883</originalsourceid><addsrcrecordid>eNpd0E1r3DAQBmBRWppNmnNuQZSSU9zOSLIt5RZCkhYC7aGF3MxYH8GpLW8l-7D_vlqyhRIQSIhnZvSKsTOEzwhCfrm-QkAwWiFCK8UbtsG6lZUB9fiWbaAVqtKtwiN2nPMzAGg06j07QlSmMXW9YbvbELxd-Bz45BIS_1E9jTs7b9O8-CHyJx89d0NO63YZ5ni5v3A-XXKKjue1z0uixXM7R-vj_lwQL6tPVKpLEf32--bZj2WMd0VO23mNLn9g7wKN2Z8e9hP26-72583X6uH7_beb64fKSg1Lhb2osTeuhprI9Q2VBMrVDgJKCBZ6HRpZogtDhtrGahesUpoITKuE1vKEXbz0LZH-rD4v3TRk68eRop_X3LUIGlCoAj--gs_zmmJ5WyeEaGqJBgo6P6C1n7zrtmmYKO26fz9awKcDoGxpDImiHfJ_DhBblH8Bw6WFIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222653190</pqid></control><display><type>article</type><title>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</title><source>Springer Link</source><creator>DAGENAIS, Claude ; JIAN ZONG ; DUCHARME, Julie ; POLLACK, Gary M</creator><creatorcontrib>DAGENAIS, Claude ; JIAN ZONG ; DUCHARME, Julie ; POLLACK, Gary M</creatorcontrib><description>This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil.
Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains.
Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo.
P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1023/A:1010984110732</identifier><identifier>PMID: 11496955</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Anesthetics. Neuromuscular blocking agents ; Animals ; Antiarythmic agents ; Antimalarials - blood ; Antimalarials - pharmacokinetics ; ATP Binding Cassette Transporter, Subfamily B - deficiency ; ATP Binding Cassette Transporter, Subfamily B - genetics ; ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics ; ATP-Binding Cassette Transporters - genetics ; ATP-Binding Cassette Transporters - pharmacokinetics ; Biological and medical sciences ; Blood-brain barrier ; Blood-Brain Barrier - genetics ; Brain - metabolism ; Brain research ; Calcium Channel Blockers - blood ; Calcium Channel Blockers - pharmacokinetics ; Cardiovascular system ; Dose-Response Relationship, Drug ; Female ; Gender differences ; Glycoproteins ; Laboratory animals ; Male ; Medical sciences ; Mice ; Mice, Knockout ; Morphine ; Morphine - blood ; Morphine - pharmacokinetics ; Narcotics - blood ; Narcotics - pharmacokinetics ; Neuropharmacology ; Perfusion - methods ; Pharmacology. Drug treatments ; Plasma ; Quinidine - blood ; Quinidine - pharmacokinetics ; Sex Characteristics ; Substrate Specificity - genetics ; Verapamil - blood ; Verapamil - pharmacokinetics</subject><ispartof>Pharmaceutical research, 2001-07, Vol.18 (7), p.957-963</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Jul 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1101171$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11496955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAGENAIS, Claude</creatorcontrib><creatorcontrib>JIAN ZONG</creatorcontrib><creatorcontrib>DUCHARME, Julie</creatorcontrib><creatorcontrib>POLLACK, Gary M</creatorcontrib><title>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil.
Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains.
Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo.
P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.</description><subject>Anesthetics. Neuromuscular blocking agents</subject><subject>Animals</subject><subject>Antiarythmic agents</subject><subject>Antimalarials - blood</subject><subject>Antimalarials - pharmacokinetics</subject><subject>ATP Binding Cassette Transporter, Subfamily B - deficiency</subject><subject>ATP Binding Cassette Transporter, Subfamily B - genetics</subject><subject>ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics</subject><subject>ATP-Binding Cassette Transporters - genetics</subject><subject>ATP-Binding Cassette Transporters - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Blood-brain barrier</subject><subject>Blood-Brain Barrier - genetics</subject><subject>Brain - metabolism</subject><subject>Brain research</subject><subject>Calcium Channel Blockers - blood</subject><subject>Calcium Channel Blockers - pharmacokinetics</subject><subject>Cardiovascular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gender differences</subject><subject>Glycoproteins</subject><subject>Laboratory animals</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Morphine</subject><subject>Morphine - blood</subject><subject>Morphine - pharmacokinetics</subject><subject>Narcotics - blood</subject><subject>Narcotics - pharmacokinetics</subject><subject>Neuropharmacology</subject><subject>Perfusion - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasma</subject><subject>Quinidine - blood</subject><subject>Quinidine - pharmacokinetics</subject><subject>Sex Characteristics</subject><subject>Substrate Specificity - genetics</subject><subject>Verapamil - blood</subject><subject>Verapamil - pharmacokinetics</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpd0E1r3DAQBmBRWppNmnNuQZSSU9zOSLIt5RZCkhYC7aGF3MxYH8GpLW8l-7D_vlqyhRIQSIhnZvSKsTOEzwhCfrm-QkAwWiFCK8UbtsG6lZUB9fiWbaAVqtKtwiN2nPMzAGg06j07QlSmMXW9YbvbELxd-Bz45BIS_1E9jTs7b9O8-CHyJx89d0NO63YZ5ni5v3A-XXKKjue1z0uixXM7R-vj_lwQL6tPVKpLEf32--bZj2WMd0VO23mNLn9g7wKN2Z8e9hP26-72583X6uH7_beb64fKSg1Lhb2osTeuhprI9Q2VBMrVDgJKCBZ6HRpZogtDhtrGahesUpoITKuE1vKEXbz0LZH-rD4v3TRk68eRop_X3LUIGlCoAj--gs_zmmJ5WyeEaGqJBgo6P6C1n7zrtmmYKO26fz9awKcDoGxpDImiHfJ_DhBblH8Bw6WFIg</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>DAGENAIS, Claude</creator><creator>JIAN ZONG</creator><creator>DUCHARME, Julie</creator><creator>POLLACK, Gary M</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</title><author>DAGENAIS, Claude ; JIAN ZONG ; DUCHARME, Julie ; POLLACK, Gary M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Anesthetics. Neuromuscular blocking agents</topic><topic>Animals</topic><topic>Antiarythmic agents</topic><topic>Antimalarials - blood</topic><topic>Antimalarials - pharmacokinetics</topic><topic>ATP Binding Cassette Transporter, Subfamily B - deficiency</topic><topic>ATP Binding Cassette Transporter, Subfamily B - genetics</topic><topic>ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics</topic><topic>ATP-Binding Cassette Transporters - genetics</topic><topic>ATP-Binding Cassette Transporters - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Blood-brain barrier</topic><topic>Blood-Brain Barrier - genetics</topic><topic>Brain - metabolism</topic><topic>Brain research</topic><topic>Calcium Channel Blockers - blood</topic><topic>Calcium Channel Blockers - pharmacokinetics</topic><topic>Cardiovascular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gender differences</topic><topic>Glycoproteins</topic><topic>Laboratory animals</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Morphine</topic><topic>Morphine - blood</topic><topic>Morphine - pharmacokinetics</topic><topic>Narcotics - blood</topic><topic>Narcotics - pharmacokinetics</topic><topic>Neuropharmacology</topic><topic>Perfusion - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasma</topic><topic>Quinidine - blood</topic><topic>Quinidine - pharmacokinetics</topic><topic>Sex Characteristics</topic><topic>Substrate Specificity - genetics</topic><topic>Verapamil - blood</topic><topic>Verapamil - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAGENAIS, Claude</creatorcontrib><creatorcontrib>JIAN ZONG</creatorcontrib><creatorcontrib>DUCHARME, Julie</creatorcontrib><creatorcontrib>POLLACK, Gary M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAGENAIS, Claude</au><au>JIAN ZONG</au><au>DUCHARME, Julie</au><au>POLLACK, Gary M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>18</volume><issue>7</issue><spage>957</spage><epage>963</epage><pages>957-963</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil.
Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains.
Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo.
P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>11496955</pmid><doi>10.1023/A:1010984110732</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0724-8741 |
ispartof | Pharmaceutical research, 2001-07, Vol.18 (7), p.957-963 |
issn | 0724-8741 1573-904X |
language | eng |
recordid | cdi_proquest_miscellaneous_71080124 |
source | Springer Link |
subjects | Anesthetics. Neuromuscular blocking agents Animals Antiarythmic agents Antimalarials - blood Antimalarials - pharmacokinetics ATP Binding Cassette Transporter, Subfamily B - deficiency ATP Binding Cassette Transporter, Subfamily B - genetics ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics ATP-Binding Cassette Transporters - genetics ATP-Binding Cassette Transporters - pharmacokinetics Biological and medical sciences Blood-brain barrier Blood-Brain Barrier - genetics Brain - metabolism Brain research Calcium Channel Blockers - blood Calcium Channel Blockers - pharmacokinetics Cardiovascular system Dose-Response Relationship, Drug Female Gender differences Glycoproteins Laboratory animals Male Medical sciences Mice Mice, Knockout Morphine Morphine - blood Morphine - pharmacokinetics Narcotics - blood Narcotics - pharmacokinetics Neuropharmacology Perfusion - methods Pharmacology. Drug treatments Plasma Quinidine - blood Quinidine - pharmacokinetics Sex Characteristics Substrate Specificity - genetics Verapamil - blood Verapamil - pharmacokinetics |
title | Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A04%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20mdr1a%20P-glycoprotein%20gene%20disruption,%20gender,%20and%20substrate%20concentration%20on%20brain%20uptake%20of%20selected%20compounds&rft.jtitle=Pharmaceutical%20research&rft.au=DAGENAIS,%20Claude&rft.date=2001-07-01&rft.volume=18&rft.issue=7&rft.spage=957&rft.epage=963&rft.pages=957-963&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1023/A:1010984110732&rft_dat=%3Cproquest_pubme%3E71080124%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222653190&rft_id=info:pmid/11496955&rfr_iscdi=true |